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Background: Benzodiazepine misuse is associated with mortality and is common among 
people who inject drugs (PWID). This study aimed to examine the temporal trends in the 
availability of benzodiazepines among PWID in a Canadian setting, and to identify factors 
associated with more immediate access to benzodiazepines.  
Methods: Data were derived from three prospective cohorts of PWID in Vancouver, 
Canada, between June 2012 and May 2015. The primary outcome was the perceived 
availability of benzodiazepines, measured in three levels: not available, delayed 
availability (available in ≥10 min), and immediate availability (available in <10 min). We 
used multivariable generalized estimating equations to identify factors associated with 
availability of benzodiazepines. 
Results: In total, 1641 individuals were included in these analyses. In multivariable 
analyses, factors associated with immediate benzodiazepine availability included 
incarceration (adjusted odds ratio (AOR): 1.42, 95% CI 1.06, 1.89) and participation in 
methadone maintenance therapy (MMT) (AOR: 1.35, 95% CI 1.14, 1.60). Factors 
associated with delayed benzodiazepine availability included incarceration (AOR: 1.45, 
95% CI 1.02, 2.07) and MMT (AOR: 1.77, 95% CI 1.48, 2.12). Benzodiazepine availability 
increased throughout the study period for both immediate (AOR: 1.14, 95% CI 1.10, 1.18 
per 6-month follow-up period) and delayed availability (AOR: 1.17, 95% CI 1.12, 1.22 per 
6-month follow-up period). 
Conclusions: Among our sample of PWID, benzodiazepine availability is increasing and 
was associated with health and criminal justice system characteristics. Our findings 
indicate a need to examine prescribing practices and educate both PWID and healthcare 
providers about the risks associated with benzodiazepine use.  
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1. INTRODUCTION 
 It is increasingly recognized that there are high rates of misuse and diversion of 
benzodiazepines and other sedatives.1-3 In the United States, 5.2% of the population filled 
at least one prescription for benzodiazepines in 2008.2 Rates of use are generally higher 
among older individuals and among females.2 In British Columbia, Canada, levels of 
benzodiazepine use have been reported to be as high as 8.4% in the general population, 
with up to 3.5% of the population filling prescriptions in excess of a 100-day 
supply.1Additionally, among people who inject drugs (PWID), it has been shown in Canada 
that up to 35% report some benzodiazepine use within the previous six months.4 Studies 
looking at benzodiazepine use in the general population have found that most 
benzodiazepine prescriptions are coming from primary care physicians.5 
Benzodiazepine use has been associated with an array of harm in the general 
population including an increased risk of falls, fractures, motor vehicle accidents, and a 
variety of serious neuropsychiatric side effects.6-8 Additionally, there is concern for 
problems with withdrawal, symptom rebound (e.g. increased panic attacks) and abuse after 
long-term use.9 At a national level, benzodiazepines were responsible for 426,000 
emergency visits in the United States in 2011.2 Among PWID, benzodiazepine use has 
been correlated with more intensive drug use, higher risk of overdose, more psychiatric co-
morbidities, poorer health and HIV/HCV seroconversion.10-14 However, even more 
troubling is that there is an association between benzodiazepines and mortality in PWID. 
This association has been studied in population-based registries.15-20 and prospective cohort 
studies,21 and these studies highlight overdose mortality in particular. There is evidence 
that benzodiazepines are associated with overdose mortality among those receiving 
methadone therapy.20 Recently a study involving PWID in Vancouver reported an increase 
in all-cause mortality associated with benzodiazepine use.22 It has been postulated that 
benzodiazepine-related psychomotor side effects leading to improper and unsafe 
preparation, dosing and injection of drugs could be one of the reasons for this 
association.23,24 Also, it has been hypothesized that PWID may be more susceptible to some 
of the more traditional risks of benzodiazepine use such as falls, motor vehicle accidents 
and fractures while under the influence of other substances.22 The harms described above 
are particularly concerning given that current evidence does not support the use of 
benzodiazepines for the treatment of chronic anxiety or insomnia disorders.25 
While the literature describes many harms associated with benzodiazepine use 
among PWID, there remain significant gaps in knowledge regarding benzodiazepine use 
in this population. To our knowledge, no study has looked at trends and factors associated 
with the availability of benzodiazepines among PWID. While many PWID who use 
benzodiazepines reportedly access them from health care providers,1,26,27 it is also known 
that diversion on the street is responsible for a large proportion of benzodiazepine 
availability.28 Identifying factors associated with a higher availability of benzodiazepines 
could inform strategies to reduce drug-related harms and decrease the availability and use 
of benzodiazepines. Therefore, our study objective was to assess the trend in 
benzodiazepine availability over time, and to identify factors associated with 
benzodiazepine availability among PWID in a Canadian setting. 
 
2. METHODS 
2.1 Study design and participants 
The Vancouver Injection Drug Users Study (VIDUS), AIDS Care Cohort to 
Evaluate exposure to Survival Services (ACCESS) and At-Risk Youth Study (ARYS) are 
open prospective cohorts of people who use illicit drugs in Vancouver, Canada. Detailed 
sampling and recruitment procedures for these cohorts have been described elsewhere.29-31 
In brief, VIDUS enrolls HIV-negative adults (≥18 years of age) who injected drugs in the 
month prior to enrolment; ACCESS enrolls HIV-positive adults (≥18 years of age) who 
used illicit drugs (other than or in addiction to cannabis) in the month prior to enrolment; 
and ARYS enrolls street-involved youth aged 14-26 years who used illicit drugs other than 
or in addition to cannabis in the month prior to enrolment. In all studies the primary modes 
of recruitment were self-referral, word of mouth, and street outreach, and residence in the 
Greater Vancouver region and written informed consent were required.   
The follow-up procedures for these studies, including the questionnaires, were 
harmonized to permit for analyses of merged data. Specifically, at baseline and 
semiannually thereafter, participants completed an interviewer-administered questionnaire 
that elicits a range of data, including demographic characteristics, drug use patterns, 
availability of drugs, and healthcare access. In addition, venous blood samples were drawn 
at each visit and used in serologic analyses, including testing for HIV and HCV antibodies 
and HIV clinical monitoring. Referral for free HIV/AIDS care was provided to participants 
in the VIDUS and ARYS cohorts found to be HIV positive, and these individuals were 
subsequently followed in the ACCESS cohort. Participants were given a stipend ($30 
CDN) at each study visit for their time. The cohort studies receive annual approval from 
the University of British Columbia/Providence Healthcare Research Ethics Board. 
The present analysis included individuals who completed at least one study 
interview between June 1, 2012 and May 31, 2015, reported a history of injection drug use 
at baseline, and provided at least one valid answer to the question regarding the availability 
of benzodiazepines during the study period. ARYS participants who initiated injecting 
drugs during the study period were included in the present study from the time point when 
they first reported injection drug use.  
2.2 Measures 
The outcome of interest in this analysis was benzodiazepine availability. At each 
study visit, participants were asked “How difficult would it be for you to get the following 
drugs right now in the area where you typically obtain your drugs? – 
Benzos/Valium/Ativan” and this was reported as either immediate availability (“score 
within 10 minutes”), delayed availability (“score within 90 minutes”, “score within 1 day”, 
or “score within > 1 day”) or no availability (“could not score”). Interviews in which 
individuals did not answer this question were not included in the GEE analysis. Participants 
were also asked to indicate the current (street) price of benzodiazepines per pill. 
We considered a number of explanatory variables including demographic, 
behavioural, clinical and other exposure characteristics as potential factors associated with 
benzodiazepine availability, based on prior studies in our setting.32-34 Socio-demographic 
variables included; gender (male vs. female); age, (per 10 years older); ethnicity/ancestry 
(Caucasian vs. other); homelessness (yes vs. no); Downtown Eastside (DTES) residency 
(yes vs. no); dealing drugs (yes vs. no); sex work (yes vs. no); and incarceration (yes vs. 
no), all in the previous six months. Vancouver’s Downtown Eastside is a neighbourhood 
with an open drug scene.35,36 Substance use behaviours included self-report of at least daily 
cocaine injection (yes vs. no), at least daily heroin injection (yes vs. no),  at least daily 
crack cocaine smoking (yes vs. no), and any history of overdose (yes vs. no), all in the 
previous six months. In addition we included benzodiazepine use ever since study 
enrolment (yes vs. no). We also considered access to any health services (i.e., a doctor, 
clinic, specialist, emergency room or hospital) in the previous six months as a potential 
explanatory variable for access to benzodiazepines. Other health-related variables 
included; involvement in methadone maintenance therapy (MMT) (yes vs. no); 
experiencing pain/discomfort (extreme or moderate vs. no); experiencing anxiety (extreme 
or moderate vs. no); mobility (limited vs. no problem); and ability to perform usual 
activities (limited vs. no problem) at the time of interview, as assessed by EQ-5D. The EQ-
5D tool has been shown to be a valid assessment of general health outcomes in a population 
of heroin users.37 We also included 6-month follow-up periods (per period later) to examine 
the temporal trends of benzodiazepine availability, and the current cohort designation 
(ARYS vs. ACCESS vs. VIDUS) to account for any potential differences among the 
cohorts in the sample characteristics.  
2.3 Statistical analyses 
As an initial analysis we calculated the proportion of each benzodiazepine 
availability category stratified by each categorical explanatory variable at the baseline. The 
categorical values were compared using the Cochran-Armitage trend test. For continuous 
explanatory variables, we calculated the median and inter-quartile range (IQR) and 
compared using the Kruskal-Wallis test. We also plotted the percentage of participants 
reporting immediate availability, delayed availability, and no availability on a line graph 
against the follow up period to illustrate the temporal trend in benzodiazepine availability.  
Next, generalized estimating equation (GEE) was used to examine the bivariable 
relationships between benzodiazepine availability and each explanatory variable. Two 
separate analyses were conducted to examine the factors associated with immediate 
availability and delayed availability, respectively. All behavioural variables were treated 
as time-varying variables. To determine the independent correlates of benzodiazepine 
availability, we fit a multivariable GEE, using a priori-defined backward stepwise 
procedure that has been used extensively in several earlier studies.38,39 Starting with a full 
model containing all variables associated with the outcome at p<0.10 in bivariable analyses, 
the quasi-likelihood under the independence model criterion (QIC) was noted, and the 
variable with the largest p-value was dropped to fit a reduced model. This iterative process 
was continued until the model had the best overall fit as indicated by the lowest QIC value.  
As a sub-analysis, we examined changes in the price of benzodiazepines during the 
study period. Because the reported prices had highly skewed distributions, we presented 
the modal price, as well as the percentage of the study sample that reported the modal price, 
as in a previous study.40 All statistical analyses were performed using SAS version 9.4 
(SAS Institute, USA). All tests of significance were two sided, and a p<0.05 was selected 
for defining statistical significance.  
 
3. RESULTS 
3.1 Sample characteristics 
A total of 1,641 individuals were eligible for the present study and were followed 
between June 2012 and May 2015. There were 6695 observations with answers about 
benzodiazepine availability, of which 1306 (19.5%) were for no availability, 1841 (27.5%) 
were for delayed availability and 3548 (53.0%) were for immediate availability. A total of 
15 participants were excluded from the analysis because they did not provide a response to 
the benzodiazepine availability question during the study period. The participants 
completed a median of 5 study visits (interquartile range [IQR]: 3 - 6). As shown in Table 
1, among the study sample, 65.4 % (1,074/1,641) were men and 59.0 % (967/1,641) were 
Caucasian. The median age was 45.0 (IQR: 33.8 – 51.8). In total, 152 (9.3 %) reported 
benzodiazepine use since the study enrolment. Of note, 127 (7.7 %) reported experiencing 
an overdose within the previous 6 months, and the rates of reporting recent overdose were 
not significantly different among the three categories of benzodiazepine availability. 
Benzodiazepine availability was highly prevalent, with 44.9 % to 54.9 % of participants 
reporting immediate availability throughout the six follow-up periods and 20.4 % to 30.1 % 
reporting delayed availability. Throughout the study period, the percentage of people 
reporting immediate and delayed availability as a combined outcome increased from 
65.3 % to 79.4 % (p<0.001). (See Figure 1 for a graphical representation of these trends.) 
3.2 GEE analyses  
The results of the bivariable and multivariable GEE analyses are presented in Table 
2. In multivariable analyses, variables independently associated with immediate 
benzodiazepine availability included Caucasian ethnicity (adjusted odds ratio [AOR]: 1.25, 
95% CI 1.04, 1.49), benzodiazepine use ever during study enrollment (AOR: 3.04, 95% CI 
2.13, 4.32), living in the DTES (AOR: 1.73, 95% CI 1.48, 2.03), drug dealing (AOR: 1.78, 
95% CI 1.45, 2.17), recent incarceration (AOR: 1.42, 95% CI 1.06, 1.89) and involvement 
in a methadone maintenance therapy program (AOR: 1.35, 95% CI 1.14, 1.60). Factors 
independently associated with delayed availability of benzodiazepines included Caucasian 
ethnicity (AOR: 1.58, 95% CI 1.32, 1.90), benzodiazepine use ever during study enrolment 
(AOR: 3.02, 95% CI 2.11, 4.32), drug dealing (AOR: 1.72, 95% CI 1.37, 2.16), recent 
incarceration (AOR: 1.45, 95% CI 1.02, 2.07) and involvement in a methadone 
maintenance therapy program (AOR: 1.77, 95% CI 1.48, 2.12). There was a trend toward 
a positive association between access to any health services and immediate availability of 
benzodiazepines (AOR: 1.20, 95% CI 0.97, 1.48); however, this result was not significant. 
Lastly, per period later in the follow-up, participants were more likely to report both 
immediate availability (AOR: 1.14, 95% CI 1.10, 1.18) and delayed availability of 
benzodiazepines (AOR: 1.17, 95% CI 1.12, 1.22). 
3.3 Pill Price  
In the sub-analysis, the modal price of benzodiazepines reported by the participants 
remained the same throughout the study period at $1 CDN per pill, reported by 42.5-54.0% 
of participants at each study visit. 
 
4. DISCUSSION 
The present study demonstrated increasing availability of benzodiazepines over 
time among cohorts of PWID in Vancouver between 2012 and 2015, while the self-reported 
price of benzodiazepines remained constant. Participants who reported a history of 
benzodiazepine use during the study period reported higher perceived availability. In 
addition, we found that the perceived availability of benzodiazepines was higher among 
people reporting residence in the DTES, drug dealing, incarceration and participation in 
methadone maintenance therapy.  
The increasing trend of perceived availability of benzodiazepines throughout our 
study period was concerning, and persisted after adjusting for key potential confounders 
including a history of benzodiazepine use, residence in the DTES, and engagement in drug 
dealing. These patterns may reflect a change in the culture of the increasing use of 
prescription drugs in society, both from the health care system and illegally.1,28 Consistent 
with our findings, Canadian studies also suggest that while the dangers of benzodiazepine 
use are becoming increasingly recognized in the scientific community, clinical practice is 
lagging and benzodiazepine prescribing among middle aged populations appears stable or 
even slightly increasing.1,27 
Participants who reported recent incarceration were significantly more likely to 
report increased availability of benzodiazepines. It is possible that this association exists 
because those with higher use of benzodiazepines had more severe addiction and related 
problems and were more likely to engage in criminal activities that could result in law 
enforcement interactions. Another possible interpretation is that through the course of 
incarceration individuals are commonly prescribed benzodiazepine to address mental 
health related issues,12 which leads to increased use (and hence increased perceived 
availability) post incarceration. If benzodiazepine prescriptions are commonly initiated in 
correctional facilities, the potential contribution of benzodiazepine use to the elevated risk 
of fatal overdose post incarceration41 warrants examination. It has been shown that 
combined opioid and sedative use is a risk factor for overdose mortality after release from 
prison.42 In this context, the association between incarceration and increased availability of 
benzodiazepines found in the present study is concerning. Additional research in this area 
should be a public health priority.  
Another troubling finding of this study is the independent association between 
engagement in MMT and easier access to benzodiazepines. Studies have shown that people 
engaged in methadone therapy have high levels of benzodiazepine use, with one study 
reporting the prevalence of past-year use at 66%.20 This might reflect the fact that those 
enrolled in MMT are more engaged with the health care system. Notably, while we did not 
find a significant association between health care utilization and benzodiazepine 
availability, there was a positive trend observed that did approach statistical significance. 
It is clear that MMT leads to many positive health and social outcomes;43-46 however, MMT 
can also be associated with drug related death, especially during times of induction into 
and cessation of therapy.47 Benzodiazepine use has also been associated with an increase 
in the risk of opioid-related death.20,47,48 The increased availability of benzodiazepines 
among patients in MMT, along with the well-studied harms in this population, highlights 
the need to intervene, through physician and patient education and public health 
interventions, to decrease inappropriate benzodiazepine prescribing and prevent these 
unintended consequences. Importantly, successful discontinuation of benzodiazepine use 
in patients engaged in methadone maintenance therapy does predict improvement in health 
outcomes including retention in treatment.49 
Increased perceived availability of benzodiazepines was independently associated 
with DTES residence and drug dealing. The DTES is a setting with an open drug market 
and public drug use35,36 and is close to a number of health care providers. In an environment 
so dense in potential sources of benzodiazepines, through both legitimately prescribed and 
illegally obtained avenues, it is expected that participants who reported residence here also 
reported relatively high availability of benzodiazepines. The independent association of 
drug dealing with perceived availability of benzodiazepines may be linked to these 
participants having direct access to personal stores of many substances of abuse, or through 
extensive personal networks throughout the drug market. More research is needed to 
investigate whether PWID are obtaining their benzodiazepines from legal or illegal sources. 
Additionally, more research is needed to examine how to restrict access to benzodiazepines 
from legal and illegal sources. 
Our study has limitations. First, as our sample was not randomly recruited, the 
generalizability of the results may be limited. Second, given the potential heterogeneity of 
drug-using populations between different communities, the results may not generalizable 
to other settings. Lastly, self-report data may be subjected to reporting biases. 
 
5. CONCLUSION 
 We found that perceived availability of benzodiazepines has increased over the 
study period among this sample of PWID. We also found several high-risk groups of PWID 
reporting more immediate availability of benzodiazepines. These included those residing 
in the DTES, those recently incarcerated, those engaged in drug dealing, and those enrolled 
in MMT. The implications of the findings related to recent incarceration or involvement in 
MMT are particularly troubling given that these sub-populations of PWID are already 
identified as being at heightened risk of fatal overdose in certain circumstances (such as 
during induction of MMT). Given the known limited clinical benefits and serious health 
harms associated with benzodiazepines, these findings indicate a need for education at the 
level of both users and prescribers, and to examine benzodiazepine prescribing practices in 
community and prison settings. As part of this, further research is needed to explore the 
exact mechanisms behind the increased availability reported in these groups and how they 
are securing their benzodiazepines, as well as to examine why availability is increasing 
over time.   
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Figure 1: Trend in availability of benzodiazepines among people who inject drugs in 
Vancouver, Canada throughout study period: June 2012 – May 2015. 
 
 
